UTHR Q3 2021 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$445M+17.0% YoY

Gross Profit

$417M93.8% margin

Operating Income

$229M51.4% margin

Net Income

$163M36.6% margin

EPS (Diluted)

$3.42

QoQ Revenue Growth

-0.4%

Cash Flow

Operating Cash Flow

$186M

Free Cash Flow

$162M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$5.0B

Total Liabilities

$1.2B

Stockholders' Equity

$3.8B

Cash & Equivalents

$909M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$445M	$380M	+17.0%
Gross Profit	$417M	$356M	+17.1%
Operating Income	$229M	$221M	+3.4%
Net Income	$163M	$171M	-5.0%

Revenue Segments

Tyvaso

$164M37%

Remodulin

$125M28%

Orenitram

$85M19%

Unituxin

$55M12%

Adcirca

$15M3%

Geographic Segments

UNITED STATES

$412M93%

European Union And Others

$33M7%